Brief: Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025
11/01/2026 18:27
Jan 11 (Reuters) - Krystal Biotech Inc KRYS.O: KRYSTAL BIOTECH INC - EXPECTS VYJUVEK NET REVENUE OF $106 MILLION TO $107 MILLION FOR Q4 2025 (ADDS DROPPED WORD 'VYJUVEK') KRYSTAL BIOTECH PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Source text: [ID:] Further company coverage: KRYS.O ((Reuters.briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion